本帖最后由 老马 于 2012-1-13 21:20 编辑 & \1 q% j+ z0 S
3 {( x! i$ s/ g3 U- ?
爱必妥和阿瓦斯丁的比较/ o( T; m+ K! b! j7 C2 Q& ~
' z5 ]$ P- ?7 K2 ~2 Yhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 Q7 K: ]7 G* k& d% }
( V$ ` Z4 L$ E1 r0 Z
( c" E- t" I( @' _
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; u( y( l! T3 C
==================================================' V, j* D Q. A2 d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 [0 Y) S. W$ x% [+ l7 x
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 P3 p7 H4 S0 v- P' G) s' i2 D' Y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.5 _1 V) |5 Z- {# j5 S4 t& [
|